Quick Answer
Prime Medicine, Inc. reported Diluted EPS of $1.35 per share (loss) for fiscal year 2025.
Prime Medicine, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.35 | +18.2% |
| 2024 | -$1.65 | +24.3% |
| 2023 | -$2.18 | +48.0% |
| 2022 | -$4.19 | +70.5% |
| 2021 | -$14.19 | -642.9% |
| 2020 | -$1.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.32 | +27.3% | +22.0% |
| June 30, 2025 | -$0.41 | +10.9% | -2.5% |
| March 31, 2025 | -$0.40 | +9.1% | +9.1% |
| September 30, 2024 | -$0.44 | +20.0% | +4.3% |
| June 30, 2024 | -$0.46 | +2.1% | -4.5% |
| March 31, 2024 | -$0.44 | +0.0% | +20.0% |
| September 30, 2023 | -$0.55 | +65.8% | -17.0% |
| June 30, 2023 | -$0.47 | +73.3% | -6.8% |
- Prime Medicine, Inc. showed an increase of +18.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Prime Medicine, Inc.’s diluted eps has grown by 29.3% (from $1.91 per share (loss) to $1.35 per share (loss)).
- The most recent figure is from Prime Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: